Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | PYGB | P11216 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14191378 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14191382 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14025371 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14278435 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL12221718 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL23640046 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL20340506 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL9914077 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL21339944 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL12242433 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024005485-A1 | SAPONIN DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS INFECTION COMPRISING SAME | 기초과학연구원 | 2024-01-04 | — | — | WO | disclosed |
| US-11839658-B2 | Aminoglycoside derivatives and nano-assemblies thereof, including those with quorum sensing inhibitory function | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-12-12 | — | — | US | disclosed |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11780872-B2 | Oligosaccharide analytical standards | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023192956-A2 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023172034-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ENVELOPED VIRUSES, COMPRISING EXTRACTS OF CODONOPSIS SP., ASTER SP. AND/OR POLYGALA SP. PLANTS | 기초과학연구원 | 2023-09-14 | — | — | WO | disclosed |
| EP-4103150-B1 | METHOD FOR PRODUCING HYDROPHILIC ORGANOPOLYSILOXANE GELS | WACKER CHEMIE AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230270110-A1 | PLANT PATHOGEN DEFENCE ELICITORS | Université Libre de Bruxelles (BE) | 2023-08-31 | — | — | US | disclosed |
| US-11739122-B2 | Glycopeptide antibiotic compounds, methods for producing the same, and uses thereof | ACADEMIA SINICA (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20120309699-A1 | COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2012-12-06 | — | — | US | disclosed |
| US-20120309699-A1 | COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2012-12-06 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110224413-A1 | CHEMICAL PROCESS | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110224413-A1 | CHEMICAL PROCESS | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-7371742-B2 | Porphyrin derivatives for photodynamic therapy | INSTITUT CURIE (FR) | 2008-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | LGALS1 184/4885LGALS3 219/4885LGALS9 283/4885 |
| US-11780872-B2 | Oligosaccharide analytical standards | OSTC, FUT5, FUT6 | LGALS1 427/4885LGALS3 312/4885LGALS9 260/4885 |
| US-11839658-B2 | Aminoglycoside derivatives and nano-assemblies thereof, including those with quorum sensing inhibitory function | FNTA, FNTB, FDPS | LGALS1 1404/4885LGALS3 1099/4885LGALS9 1751/4885 |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | LGALS1 428/4885LGALS3 613/4885LGALS9 784/4885 |
| US-20230270110-A1 | PLANT PATHOGEN DEFENCE ELICITORS | LPO, LCT, MGAM | LGALS1 140/4885LGALS3 206/4885LGALS9 210/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | LGALS1 184/4885LGALS3 219/4885LGALS9 283/4885 |
| US-20110224413-A1 | CHEMICAL PROCESS | SLC5A2, SLC5A1, UGGT1 | LGALS1 321/4885LGALS3 261/4885LGALS9 364/4885 |
| US-20120309699-A1 | COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY | FABP2, TNF, NFKBIA | LGALS1 202/4885LGALS3 362/4885LGALS9 198/4885 |
| US-11739122-B2 | Glycopeptide antibiotic compounds, methods for producing the same, and uses thereof | NGLY1, NRDC, MGAT3 | LGALS1 513/4885LGALS3 529/4885LGALS9 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.